Tokyo, Japan, June 3, 2022 - JSR Corporation (Head Office: Minato-ku, Tokyo, Representative Director and CEO: Eric Johnson, JSR Corporation) announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome, for the Collaborative Lab, a collaborative research facility for startups, which was established in a new research laboratory at the "JSR Bioscience and Informatics R&D Center (JSR BiRD)" in Kawasaki City, Kanagawa Prefecture last July. KINS will be the first company to use the Collaboration Lab since JSR BiRD opened.
KINS is a health technology company that supports the care of microbiome, which is responsible for health and vitality throughout the body, and accelerates research while building and analyzing databases of microbiome samples from skin, scalp, intestines, and more. The company recently expanded its business to include the microbiome of dogs and cats and plans to develop products and services to enter the pharmaceutical field.
JSR is continuing to develop its life sciences business, mainly diagnostic reagent materials, bioprocess materials, and drug discovery and development support business. At the same time, the company is engaged in research on the microbiome as a next generation technology with a focus on innovation leading to new products and services required for a healthy and long-living society. Through collaborative research with KINS, we aim to further accelerate and next generation research.
Business: Development, manufacture, sales of supplements and cosmetics, and analysis and construction of database for microbiome
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
JSR Life Sciences to Launch Amsphere™ A+, a Next-Generation Protein A Resin for Antibody Drug Purification
Amsphere™ A+ enhances antibody drug production with advanced polymer technology and high binding capacity, debuting at BPI 2024 and BioJapan.
JSR Active Innovation Fund LLC invests in Aillis, Inc., which develops and sells AI medical devices
JSR-AIF participated in the Series D financing of Aillis for the purpose of raising funds to accelerate research and development of AI medical devices, sales, and marketing promotion
JSR Begins Development of Raw Materials from Biomass
Through joint development with Bacchus Bio innovation, JSR will develop and produce raw materials for its key biomass products utilizing synthetic biology.
Ajinomoto Co., Inc. and JSR Corporation Agree to Collaborate in Development of Global Biopharmaceutical Culture Media...
Ajinomoto Co. has reached an agreement with JSR to collaborate on the global expansion of its biopharmaceutical culture media business, adding new high-performance media developed by JSR, to Ajinom...
JSR Invites AuB Co., Ltd. to Kawasaki Collaborative Research Facility, JSR BiRD, Challenging Value Creation in the Mi...
JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.